Effect of lamivudine treatment on plasma levels of transforming growth factor &beta;1, tissue inhibitor of metalloproteinases-1 and metalloproteinase-1 in patients with chronic hepatitis B

doi:10.3748/wjg.v10.i18.2661

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 18

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2983)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-5) series.

Item

Count

PDF

288

HTML

2291

Figures (1-4)

195

Tables (1-5)

209

Sum=2983

Sep 15, 2004 (publication date) through Nov 28, 2024

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Viral Hepatitis

World J Gastroenterol. Sep 15, 2004; 10(18): 2661-2665
Published online Sep 15, 2004. doi: 10.3748/wjg.v10.i18.2661

Full Size Figure Download Figure

Figure 4 Mean MMP-1 plasma concentrations before and during lamivudine therapy as well as 24 wk after its completion (week 72) in respect to the final effect of the treatment. Statistical significance in comparison to normal values are indicated with asterisks and between groups with arrows.

Citation: Flisiak R, Al-Kadasi H, Jaroszewicz J, Prokopowicz D, Flisiak I. Effect of lamivudine treatment on plasma levels of transforming growth factor β₁, tissue inhibitor of metalloproteinases-1 and metalloproteinase-1 in patients with chronic hepatitis B. World J Gastroenterol 2004; 10(18): 2661-2665
URL: https://www.wjgnet.com/1007-9327/full/v10/i18/2661.htm
DOI: https://dx.doi.org/10.3748/wjg.v10.i18.2661